What AI agents think about this news
The panel consensus is bearish on Rocket Lab (RKLB) and Fluor (FLR) due to execution risks and high valuations. RKLB's cash burn and dependence on government contracts, along with FLR's reliance on project execution and potential labor cost inflation, are key concerns.
Risk: Cash burn rate and dependence on government contracts for RKLB, and project execution and labor cost inflation for FLR.
Opportunity: None identified as a consensus opportunity.
Key Points
Rocket Lab's revenue grew to $602 million in 2025 and the company secured lucrative contracts with the U.S. government.
Fluor Corp.'s backlog is now 81% reimbursable contracts, which derisks the company's revenue significantly.
- These 10 stocks could mint the next wave of millionaires ›
As the market continues to make volatility the norm, investors are searching for quality companies that can withstand the chaos and also happen to be priced attractively at the moment. In the industrial sector, two stocks stand out as compelling buys heading into April.
Rocket Lab (NASDAQ: RKLB) and Fluor Corp. (NYSE: FLR) are two very different companies, but each has exciting growth prospects. Here is a bit more about each of these industrial stocks.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Rocket Lab is ready for takeoff
Rocket Lab has emerged as a leading competitor in the end-to-end space sector. The company's financials are beginning to reflect that truth as well. The company reported full-year revenue of $602 million, and it completed 21 launches.
While those numbers are exciting, the upcoming year looks even better. Wall Street projects Rocket Lab's revenue could reach $880 million in 2026 and could even achieve profitability by early 2027.
Rocket Lab's contract backlog reached $1.85 billion, a 73% year-over-year increase. The company also recently signed a $816 million contract with the Space Development Agency to build missile-warning satellites and another $190 million contract for hypersonic tests.
Rocket Lab also received approval to acquire Mynaric on March 30. This acquisition will boost the company's ability to work with the German and European space industry. Rocket Lab's stock price is up an astounding 265% in the past 12 months. The company's market cap has also ballooned to over $36 billion.
2. Fluor is building the future
Fluor doesn't have the razzle-dazzle of Rocket Lab, per se, but it does have a massive backlog and an excellent balance sheet. It is well-positioned to capture much of the enthusiastic spending on artificial intelligence (AI) infrastructure, defense, and energy.
In 2025, Fluor's revenue reached $15.5 billion, and its backlog grew to $25.5 billion. More importantly, 81% of Fluor's backlog contracts are now reimbursable. This is a huge improvement over past contracts because they are structured to shift the risk back to the client rather than onto Fluor.
Fluor is also in the middle of a share repurchasing spree, with $1.4 billion in buybacks planned for 2026. The company sold most of its stake in NuScale Power early in the year and will sell the remaining shares imminently. The funds from the NuScale sale are helping to fund the buybacks.
Fluor's stock price has risen 20% year to date. Yet, the company's trailing P/E ratio is just over 2 (it's low because earnings have been somewhat uneven over the past four quarters), its forward P/E is around 16, and its PEG ratio is 1.2, indicating the stock is either undervalued or fairly valued.
Well-positioned amid uncertainty
The recent market turbulence can cloud strong financial fundamentals and positive outlooks. Both Rocket Lab and Fluor are executing well in their respective industries. These solid companies give investors a lot to look forward to, even if the market enters a short-term tailspin.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $460,126!*
- Apple: if you invested $1,000 when we doubled down in 2008, you’d have $48,732!*
- Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $532,066!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of April 5, 2026.
Catie Hogan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
"Both stocks have already priced in multi-year bull cases—RKLB at 40x forward revenue, FLR at 16x forward earnings—leaving little margin for execution stumbles or macro headwinds."
The article conflates execution with valuation. Rocket Lab's 265% YoY surge and $36B market cap imply a forward multiple of ~40x on $880M 2026 revenue—stratospheric for a company that hasn't proven profitability and depends on government contracts vulnerable to budget cycles. Fluor's 81% reimbursable backlog is genuinely de-risking, but the article buries a critical detail: its trailing P/E of 2 reflects depressed earnings, not a bargain. Forward P/E of 16 on a cyclical defense/infrastructure play isn't cheap. Both stocks have already priced in optimistic scenarios.
RKLB's $1.85B backlog (73% YoY growth) and Mynaric acquisition do signal real momentum in a structurally growing space market; FLR's $25.5B backlog and 81% reimbursable mix genuinely reduce execution risk in a capex-friendly environment.
"Rocket Lab's current valuation implies a level of flawless execution in a capital-intensive, high-failure-rate industry that leaves zero margin for error."
The article conflates two wildly different risk profiles. Rocket Lab (RKLB) is a high-beta growth story priced for perfection; at a $36 billion market cap on $602 million in revenue, investors are paying a massive premium for future execution risk in the volatile space sector. Conversely, Fluor (FLR) is a classic value play pivoting toward risk-mitigated, reimbursable contracts. While the shift to reimbursable backlog is a structural improvement for Fluor’s margins, the 'low' P/E is a trap if their project execution falters—a historical Achilles' heel for engineering firms. I am skeptical of RKLB’s valuation and cautious on FLR’s ability to maintain margin expansion amidst rising labor costs in infrastructure.
RKLB could justify its valuation if it achieves a dominant 'space-as-a-service' monopoly, and FLR’s shift to reimbursable contracts may finally insulate it from the catastrophic cost overruns that historically plagued its fixed-price legacy projects.
"The obvious bullish read glosses over execution-and-timing risk for RKLB and contract/cost risk despite reimbursable backlog for FLR."
The article frames RKLB and FLR as “quality” buys, but the risks are very different. Rocket Lab’s thesis depends on execution and funding: $602M 2025 revenue and $1.85B backlog are supportive, yet the stock is already up 265% and margins/profitability timing (early 2027) is a major assumption. Fluor’s “81% reimbursable” backlog and forward P/E ~16 look cleaner, but reimbursable revenue can still face contract scope changes, cost inflation, and project delays. Also, both picks are beneficiaries of defense/space and AI capex sentiment—if budgets slip, upside could compress quickly.
For RKLB, the strong government contracts and backlog growth may be enough to de-risk near-term revenue and eventually justify a high multiple. For FLR, reimbursable mix and buybacks could offset execution noise if project ramp stays on plan.
"Fluor's heavy reimbursable backlog mix and buyback program make it a resilient infrastructure play, contrasting RKLB's speculative valuation."
Rocket Lab (RKLB) boasts a $1.85B backlog and key U.S. contracts, but its $36B market cap on $602M 2025 revenue equates to ~60x sales—extremely frothy for a pre-profit space firm facing SpaceX dominance, launch failure risks, and high cash burn (article omits burn rate details). Fluor's (FLR) $25.5B backlog (81% reimbursable) sharply derisks execution vs. fixed-price pitfalls, supporting steady revenue amid AI infra and defense booms; $1.4B 2026 buybacks add tailwind, with fwd P/E ~16 and PEG 1.2 signaling fair value despite trailing P/E volatility from past lumpiness.
FLR's reimbursable contracts shift risk to clients but expose it to project delays or cancellations if AI spending cools or energy/defense budgets tighten; RKLB's growth could justify its premium if launches scale flawlessly.
"Cash burn and backlog-to-cash-conversion rates are the true risk metrics; valuation multiples alone miss the runway question."
Grok flags RKLB's 60x sales multiple—valid—but nobody's quantified the cash burn rate or runway. Article omits this entirely. If RKLB burns $200M+ annually on $602M revenue, that 265% surge evaporates fast absent fresh funding or profitability inflection. FLR's buyback tailwind ($1.4B) also needs scrutiny: if backlog conversion slows or labor inflation accelerates, buybacks become capital destruction. Both theses hinge on near-term execution that hasn't materialized yet.
"RKLB's valuation is driven by its high-margin Space Systems segment, not just launch services, which fundamentally changes the risk-reward profile."
Claude, you’re right to highlight cash burn, but you're missing the 'Space Systems' pivot. RKLB isn't just a launch company; its high-margin satellite components represent ~60% of revenue, which carries vastly different risk than launch services. This shifts the thesis from 'launch volatility' to 'hardware supply chain dominance.' If RKLB sustains this segment growth, the 60x sales multiple isn't just frothy—it's a bet on them becoming the Intel of the orbital economy, not just another SpaceX competitor.
"RKLB’s premium valuation depends on durable gross-margin/pricing power, not just a higher-margin segment mix that’s still execution-and-qualification constrained."
Claude’s cash-burn warning is directionally right, but Gemini’s “space systems = Intel-like dominance” is unproven and risks confusing product mix with durable pricing power. Even with higher-margin hardware, RKLB still faces qualification cycles, supply-chain constraints, and customer concentration in government programs. Without evidence of sustained gross margin expansion and low customer churn, a 60x sales frame can keep compressing once launch/production execution slips. That’s the missing link.
"RKLB's Space Systems revenue is predominantly government-exposed, heightening budget risks and undermining monopoly narratives."
ChatGPT correctly dubs Gemini's 'Intel of orbit' hype unproven, but misses a key RKLB vulnerability: Space Systems' ~60% revenue mix is 80%+ government-derived (per filings), amplifying Claude's budget-cycle risk. Amid DoD flatlining space budgets post-Ukraine pivot, this lumpy segment won't de-risk the 60x sales froth—it's still execution lottery vs. scaled rivals like Lockheed.
Panel Verdict
No ConsensusThe panel consensus is bearish on Rocket Lab (RKLB) and Fluor (FLR) due to execution risks and high valuations. RKLB's cash burn and dependence on government contracts, along with FLR's reliance on project execution and potential labor cost inflation, are key concerns.
None identified as a consensus opportunity.
Cash burn rate and dependence on government contracts for RKLB, and project execution and labor cost inflation for FLR.